腺病毒载体和mRNA新冠疫苗第二剂加强针提高对新冠住院的保护:REFORCO-Brazil真实世界有效性研究Omicron期间最终分析
REFORCO-Brazil是一项检测阴性病例对照研究,利用巴西国家SARS监测和新冠疫苗接种数据,评估2022年第二剂加强针相对于第一剂加强针对新冠住院的相对疫苗有效性。总体rVE为18.7%(95%CI:10.5-26.1),腺病毒载体和mRNA疫苗相似,在非常高龄和免疫缺陷/高风险人群中观察到类似额外保护。
要点
- 任何第二剂加强针相比第一剂加强针对新冠住院的总体rVE为18.7%(95%CI:10.5-26.1)。
- 腺病毒载体和mRNA疫苗rVE相似:AZD1222为18.2%、Ad26.COV2·S为20.7%、BNT162b2为23.2%。
- 接种后2个月内额外保护最高,此后下降;探索性分析显示对院内严重结局包括死亡的保护增加。
核心结论
- 结果支持使用单价腺病毒载体/mRNA疫苗维持对Omicron亚变异株所致新冠住院的保护。
- 未来加强针策略需仔细考虑最佳接种时机,尤其在脆弱亚组中。
研究设计与样本
- REFORCO-Brazil为检测阴性病例对照研究(NCT05697705),利用巴西国家SARS监测和新冠疫苗接种数据。
- 2022年1月1日至12月31日因SARS住院者分为检测阳性病例(SARS-CoV-2抗原/RT-PCR)和检测阴性对照(RT-PCR),按入院日期、地区、性别、既往新冠疫苗接种和年龄匹配。
- 采用条件logistic回归结合多协变量调整估计第二剂加强针(相比≥4个月前接种的第一剂加强针)的rVE。
主要发现
- 5426例检测阳性病例和6131例检测阴性对照中,第二剂加强针至SARS住院的中位(范围)时间分别为87.0(8.0-307.0)天和79.0(8.0-303.0)天。
- 任何第二剂加强针对住院的总体rVE为18.7%(95%CI:10.5-26.1)。
- AZD1222的rVE为18.2%(95%CI:4.8-29.8),Ad26.COV2·S为20.7%(95%CI:10.2-30.0),BNT162b2为23.2%(95%CI:9.7-34.7)。
- 在非常高龄和免疫缺陷/高风险个体中观察到类似水平的额外保护效益。
- 接种后2个月内额外保护最高,此后下降;探索性分析显示对院内严重结局包括死亡的保护增加。
临床怎么用
- 作者结论支持使用单价腺病毒载体/mRNA疫苗维持对Omicron亚变异株所致新冠住院的保护。
- 作者指出未来加强针策略需仔细考虑最佳接种时机,尤其在脆弱亚组中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Booster doses of COVID-19 vaccines are required to maintain protection against SARS-CoV-2. However, real-world evidence from South America, needed to inform optimal vaccination strategies, is lacking. Herein, we present the final analysis of REFORCO-Brazil, a large-scale assessment of relative vaccine effectiveness (rVE) of second boosters (vs first boosters) against hospitalization with COVID-19. METHODS: REFORCO-Brazil is a test-negative case-control study (NCT05697705) that utilized Brazilian national data on severe acute respiratory syndrome (SARS) surveillance and COVID-19 vaccination. Individuals hospitalized with SARS from January 1 to December 31, 2022, were classified as test-positive cases (via SARS-CoV-2 antigen/reverse transcription polymerase chain reaction [RT-PCR]) or test-negative case-controls (via RT-PCR) and matched by admission date, region, sex, preceding COVID-19 vaccinations, and age. We used conditional logistic regression combined with multiple covariate adjustments to estimate rVE for second boosters (versus first boosters received ≥4 months prior) overall, by type (AZD1222, Ad26.COV2·S, BNT162b2, and CoronaVac) and in vulnerable subgroups (elderly and immunocompromised/high-risk individuals). RESULTS: Median (range) time between second booster and SARS hospitalization was 87.0 (8.0-307.0) and 79.0 (8.0-303.0) days among 5426 test-positive cases and 6131 test-negative controls, respectively. Overall rVE of any second booster against hospitalization was 18.7 % (95 % confidence interval [CI]: 10.5-26.1). The rVE of adenoviral- and mRNA-based vaccines was similar; 18.2 % (4.8-29.8) for AZD1222, 20.7 % (10.2-30.0) for Ad26.COV2·S, and 23.2 % (9.7-34.7) for BNT162b2. Similar levels of added protective benefit, or 'boosting', was observed in very elderly and immunocompromised/high-risk individuals. Additional protection was highest within 2 months post-dosing, decreasing thereafter. Exploratory analyses revealed increased protection against severe in-hospital outcomes, including mortality. CONCLUSIONS: Our results support the use of monovalent adenoviral/mRNA-based vaccine maintain protection against COVID-19 hospitalization from Omicron subvariants. However, optimal timing of booster vaccinations will need to be carefully considered for future booster strategies, especially among vulnerable subgroups.
引用
- Meeraus W, Postema A, Gray CM, et al. Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron. Vaccine. 2025. PMID: 40068393. doi:10.1016/j.vaccine.2025.126955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。